New Risk • Aug 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 43% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (UK£2.7m revenue, or US$3.7m). Market cap is less than US$100m (UK£15.0m market cap, or US$20.3m). Announcement • Jun 01
ProBiotix Health Plc, Annual General Meeting, Jun 23, 2026 ProBiotix Health Plc, Annual General Meeting, Jun 23, 2026. Location: the offices of albr capital limited, 3rd floor 80 cheapside, london ec2v 6ee United Kingdom Board Change • May 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non-Executive Director Frederik Bruhn-Petersen was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Mar 31
Full year 2025 earnings released: UK£0.008 loss per share (vs UK£0.006 loss in FY 2024) Full year 2025 results: UK£0.008 loss per share (further deteriorated from UK£0.006 loss in FY 2024). Revenue: UK£2.73m (up 45% from FY 2024). Net loss: UK£1.23m (loss widened 46% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. New Risk • Mar 27
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 45% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (UK£2.2m revenue, or US$3.0m). Market cap is less than US$100m (UK£11.1m market cap, or US$14.7m). New Risk • Mar 20
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 45% per year over the past 5 years. Minor Risks Revenue is less than US$5m (UK£2.2m revenue, or US$3.0m). Market cap is less than US$100m (UK£12.3m market cap, or US$16.3m). Announcement • Mar 16
ProBiotix Health Plc to Report Fiscal Year 2025 Results on Mar 30, 2026 ProBiotix Health Plc announced that they will report fiscal year 2025 results on Mar 30, 2026 New Risk • Feb 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Revenue is less than US$5m (UK£2.2m revenue, or US$3.0m). Market cap is less than US$100m (UK£12.3m market cap, or US$16.7m). New Risk • Dec 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Revenue is less than US$5m (UK£2.2m revenue, or US$3.0m). Market cap is less than US$100m (UK£11.9m market cap, or US$15.9m). Board Change • Oct 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Frederik Bruhn-Petersen was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jul 15
ProBiotix Health Plc to Report First Half, 2025 Results on Sep 08, 2025 ProBiotix Health Plc announced that they will report first half, 2025 results on Sep 08, 2025 Announcement • May 30
ProBiotix Health Plc, Annual General Meeting, Jun 27, 2025 ProBiotix Health Plc, Annual General Meeting, Jun 27, 2025. Location: the offices of gerald edelman, 73 cornhill, ec3v 3qq, london United Kingdom Announcement • May 07
ProBiotix Health Plc to Report Fiscal Year 2024 Results on May 29, 2025 ProBiotix Health Plc announced that they will report fiscal year 2024 results on May 29, 2025 New Risk • Mar 18
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (9.4% average weekly change). Shareholders have been diluted in the past year (30% increase in shares outstanding). Revenue is less than US$5m (UK£2.1m revenue, or US$2.8m). Market cap is less than US$100m (UK£15.8m market cap, or US$20.5m). New Risk • Nov 26
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.91m (US$9.92m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 26% per year over the past 5 years. Market cap is less than US$10m (UK£7.91m market cap, or US$9.92m). Minor Risks Shareholders have been diluted in the past year (30% increase in shares outstanding). Revenue is less than US$5m (UK£2.1m revenue, or US$2.7m). New Risk • Sep 03
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£1.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.1m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 26% per year over the past 5 years. Market cap is less than US$10m (UK£5.47m market cap, or US$7.18m). Minor Risk Revenue is less than US$5m (UK£2.1m revenue, or US$2.8m). Announcement • Jul 30
Probiotix Health plc Appoints Cellan Davies as New Head of Marketing ProBiotix Health plc announced it has appointed Cellan Davies as its new Head of Marketing as of 5 July 2024. Cellan's role will be to implement new innovative marketing strategies and enhance customer acquisition efforts. Through his previous roles with leading global brands such as Lab4 Probiotics by Cultech Ltd. and ProVen Probiotics, as well as European companies PRP Supplements and Aliment Nutrition, Cellan has been instrumental in implementing marketing and communication strategies across B2B, B2C and D2C segments within the supplement and nutrition industry. He has worked with ProBiotix for two years in a part time capacity before now transitioning to a fulltime role. He brings more than ten years of commercial and marketing experience in the supplements and nutrition industry, and a specialised focus on probiotics for the past eight years. Reported Earnings • Jul 01
Full year 2023 earnings released: UK£0.006 loss per share (vs UK£0.002 loss in FY 2022) Full year 2023 results: UK£0.006 loss per share (further deteriorated from UK£0.002 loss in FY 2022). Revenue: UK£1.67m (up 28% from FY 2022). Net loss: UK£747.0k (loss widened 247% from FY 2022). Announcement • Jun 30
ProBiotix Health Plc, Annual General Meeting, Aug 08, 2024 ProBiotix Health Plc, Annual General Meeting, Aug 08, 2024. Location: the offices of peterhouse capital limited, 3rd floor, 80 cheapside, ec2v 6ee, london United Kingdom New Risk • May 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.5% per year over the past 5 years. Market cap is less than US$10m (UK£6.08m market cap, or US$7.76m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (UK£1.6m revenue, or US$2.0m). New Risk • Apr 14
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.5% per year over the past 5 years. Market cap is less than US$10m (UK£6.69m market cap, or US$8.33m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (UK£1.6m revenue, or US$1.9m). New Risk • Mar 11
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.60m (US$9.74m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 5.5% per year over the past 5 years. Market cap is less than US$10m (UK£7.60m market cap, or US$9.74m). Minor Risk Revenue is less than US$5m (UK£1.6m revenue, or US$2.0m). New Risk • Oct 05
New major risk - Revenue and earnings growth Earnings have declined by 5.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 5.5% per year over the past 5 years. Market cap is less than US$10m (UK£7.91m market cap, or US$9.61m). Minor Risk Revenue is less than US$5m (UK£1.6m revenue, or US$1.9m). Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Announcement • Jun 20
Probiotix Health plc Announces Appointment of Steen Andersen as Chief Executive Officer On 14 June 2022 ProBiotix Health plc announced that Steen Andersen ("Steen") has been appointed as Chief Executive Officer ("CEO"), and that Steen will join the company after completing his notice period with his current employer. The Company has a 44% shareholding in ProBiotix Health. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Apr 01
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 
